Metropolis Healthcare Limited has informed the Exchange about the Acquisition of Dr. RS Patil s Ambika Pathology Laboratory
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 0.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board has approved acquiring Dr. RS Patil's Ambika Pathology Laboratory, a sole proprietorship based in Kolhapur, Maharashtra, for a total cash consideration of INR 17 crore (including INR 1.7 crore deferred) on a slump sale basis, expected to close within 45 days. The target is a NABL-accredited lab established in 1995, with 12 patient touch points and FY25 turnover of INR 7.96 crore, and the deal needs no regulatory approvals. Metropolis says the buy strengthens its leadership in Kolhapur and lays the groundwork for a mini reference lab serving 4–5 districts in Western Maharashtra. Separately, Q1 FY26 standalone revenue rose about 13% year-on-year to Rs. 323.6 crore with profit of Rs. 35.6 crore (EPS Rs. 6.87), while consolidated revenue grew about 23% to Rs. 386.1 crore with profit of Rs. 45.2 crore (EPS Rs. 8.70).
The acquisition is a small, tuck-in deal (roughly 5% of standalone quarterly revenue) and is unlikely to move the needle on near-term financials, though it deepens regional dominance in Western Maharashtra. The strong Q1 print, with healthy double-digit growth in both standalone and consolidated profits, should support investor sentiment.